

Analyst Report

[français – english]

Galina Sotnikova-Anquez
Jean-Pierre Loza, PhD



Intrasense

Euronext Growth Paris : ALINS [FR0011179886]

22/03/2018

Estimated Share Price : € 1,2

Estimated Market Cap. (€M)*	13,3	YTD High/Low (€)	0,88/0,39
Share price (€)*	0,71	3-month average daily vol.	1 141 883
Market Cap. (€M)*	7,8	Free Float	2%
Number of shares (M)	11,1	Estimated Net Cash (€M)	0,8
Eligibility to PEA	YES	Closing date of the accounts	12/31/18

* as of 22/03/2018

With 12 Sigma Technologies, Intrasense strengthens its Chinese strategy

Intrasense announced today that it has signed a strategic partnership agreement with 12 Sigma Technologies. With this contract, the second signed by the Montpellier company since the beginning of the year, marks not only its entry into the field of artificial intelligence, but also the strengthening of its positions in the Chinese market. Our team increases the objective at € 1.2 per share.

12 Sigma Technologies, a player in artificial intelligence

Using Myrian® Studio, the Myrian® platform development tool of Intrasense, 12 Sigma has developed "σ-Discover Lung", a computer-assisted diagnostic aid for the analysis of lung diseases. Specialist in artificial intelligence and

Avec 12 Sigma Technologies, Intrasense renforce sa stratégie chinoise

Hier Intrasense a annoncé avoir signé un contrat de partenariat stratégique avec la société 12 Sigma Technologies. Avec ce contrat, le second signé par la société montpelliéraine depuis le début d'année, Intrasense marque non seulement son entrée dans le domaine de l'intelligence artificielle, mais aussi le renforcement de ses positions sur le marché chinois. Notre équipe augmente l'objectif du cours à € 1,2 par action.

12 Sigma Technologies, un acteur de l'intelligence artificielle

En s'appuyant sur Myrian® Studio, l'outil de développement de la plateforme Myrian® d'Intrasense, 12 Sigma a développé « σ-Discover Lung », un système d'aide au diagnostic assisté par ordinateur pour l'analyse des affections

neural networks, using Myrian® Studio, 12 Sigma has developed a solution to compile many lung images, in the order of one million. This method applies deep learning methods, or supervised learning, that consists in recognizing the content of an image, then comparing it in a trial-error or learning-classification process to different image banks. The 12 Sigma deep learning could detect lesions as small as 0.1% of an image, to allow early diagnosis of pathologies as well as the planning and monitoring of treatments.

China, one of Intracense's target markets

With nearly a hundred hospital customers in China, 12 Sigma Technologies is set to become a major player in the sector. In addition, the company is also present on the American territory, with its San Diego base. Intracense strengthened its presence in China, a market with great potential for the company (2nd health world market). Indeed, after the signing of a research cooperation agreement with MinFound Medical Systems, manufacturer of medical imaging equipment, on February 5th, 2018, this is the second contract signed with a Chinese company, this year. In addition, it is the sixth signed agreement resulting from a collaboration started using Myrian® Studio.

Valuation

The strategy put in place by Intracense management, focused on key accounts, highlighting innovation via Myrian® Studio and Myrian® Imaging Layer, and on more industrial partners, should be fully operational by 2018. Aurgalys Value team team increases the price target to € 1.2 per share.

pulmonaires. Spécialiste de l'intelligence artificielle et des réseaux de neurones, en utilisant Myrian® Studio, 12 Sigma a développé une solution permettant de compiler un grand nombre d'images pulmonaires, de l'ordre du million. Cette méthode utilise le « deep learning » (apprentissage profond) ou encore apprentissage supervisé, lequel consiste à reconnaître le contenu d'une image et à le comparer dans un processus d'essai-erreur ou apprentissage-classification à des banques d'images différentes. Le deep learning de 12 Sigma détecte des lésions aussi petites que 0.1% d'une image, il devrait ainsi permettre des diagnostics précoces de pathologies ainsi que la planification et le suivi des traitements.

La Chine, l'un des marchés cibles d'Intracense

Avec près d'une centaine de hôpitaux clients en Chine, 12 Sigma Technologies est en passe de devenir un acteur majeur du secteur. De plus, la société est aussi présente sur le territoire américain à San Diego. Intracense renforce ainsi sa présence en Chine, marché présentant un grand potentiel pour la société (2^{ème} marché de la santé mondiale). En effet, après la signature de l'accord de coopération de recherche avec MinFound Medical Systems, fabricant de matériel d'imagerie médicale, le 5 février 2018, il s'agit du sixième contrat signé avec une société chinoise cette année. Par ailleurs, c'est le second accord signé issu d'une collaboration débutée par l'utilisation de Myrian® Studio.

Valorisation

La stratégie mise en place par le management d'Intracense, avec un focus sur les grands comptes, la mise en avant des innovations produits Myrian® Studio et Myrian® Imaging Layer, de nouveaux partenaires industriels, devrait s'exprimer pleinement en 2018. Notre équipe augmente l'objectif de cours à € 1,2 par action.


Euronext since/ depuis March 22th, 2017

Intrasense	+8%
Alys France*	-18,5%
Next Biotech	+21%
CAC Healthcare	-9,6%
CAC 40	+3,4%
CAC Small	+13%

*Index of French smallcaps (less than €1B market capitalization at time of inclusion) in the healthcare and life sciences sector, listed on Euronext Paris
See <http://www.aurgalys.com/aurgalys-indices>

Intrasense one-year stock performance, by comparison with Alys France Index, as of March 22th, 2018

Performance à un an d'Intrasense en comparaison avec l'indice Alys France, au 22 mars 2018



Disclaimer

This study has been prepared based on general and public information assumed to be complete, exact and pertinent. Although all necessary precautions have been taken to assure that the information used originates from reliable sources, Aurgalys does not guarantee the accuracy or completeness of this report. Neither Aurgalys nor any of its associates may be held liable in any manner whatsoever in the event that any of the documents and other information on which the study has been based proves to be inaccurate and in any way resulting in the possible misrepresentation of the economic and financial position of the Company or any other relevant information. The valuation contained herein has been prepared in accordance with the best assessment of Aurgalys as at the date of preparation of this study and has been based on the information as described above. Neither Aurgalys nor its associates guarantee that the value so obtained will correspond or coincide with the price that could effectively be paid in a transaction or established in a negotiation or any transaction or calculation involving the Company. This document does not constitute an offer or an invitation to buy or subscribe to negotiable or other securities. It may not be used in any manner in support of or in connection with any contract or commitment. This document is being supplied for information purposes only and may not be reproduced or passed on to any third party without the written authorization of Aurgalys. This document has been provided to the Company prior to its distribution. Aurgalys does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. You may call +33(0)1 75 66 20 53 or write to g.sotnikova@aurgalys.com to request a copy of this independent research

About Aurgalys

First company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext).

Aurgalys

1, rue Pierre Fontaine, 91058 Evry Cedex,
France
www.aurgalys.com

Join us on

[Linkedin](#)

Follow us on

Twitter [@aurgalys](#)